Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009
N/A. All patients aged 18 or older who received a lung or heart/lung transplant from
January 1, 2002 through December 31, 2009 in the MarketScan database were sampled.
Observational Model: Cohort, Time Perspective: Retrospective
Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC)
Baseline until non-melanoma skin cancer diagnosis, loss-to-follow-up due to death or termination of the health plan or end of the study, assessed up to Year 8
Pfizer CT.gov Call Center
United States: Food and Drug Administration